Commonly used blood test may not pick up kidney disease for people in Africa

A commonly used blood test which measures how well a person's kidneys are working may not pick up kidney disease for people in Africa, according to a study published in The Lancet Global Health.

Researchers from the African Research on Kidney Disease (ARK) Consortium - which includes the London School of Hygiene & Tropical Medicine (LSHTM) and the Medical Research Council/Uganda Virus Research Institute and London School of Hygiene & Tropical Medicine Uganda Research Unit (MRC/UVRI and LSHTM Uganda Research Unit) - ran the study.

It focused on more than 2,500 people in Malawi, South Africa and Uganda and was the largest study to analyze kidney disease testing and prevalence in Africa.

The findings suggest that methods developed in high-income settings to check kidney function are not accurate for many people in Africa, meaning many people could miss early diagnosis and life-saving treatment.

Testing how well kidneys function is essential to diagnosing kidney disease in individuals and predicting the burden of disease in populations.

Glomerular filtration rate (GFR) is the most common way to assess kidney function and is a measure of how much blood the kidneys are filtering per minute.

Testing kidney function involves measuring how much creatinine or cystatin C is in a person's blood. Creatinine is a by-product of muscle breakdown while cystatin C is a protein made by cells in the body. Healthy kidneys filter creatinine or cystatin C out of the blood and excrete these in urine. A creatinine or cystatin C test thus measures how well kidneys are performing. High levels can be a sign that the kidneys are not functioning properly.

To study the most accurate way to measure kidney function in African populations, the ARK Consortium compared the widely used creatinine and cystatin C-based tests with a benchmark test called the iohexol measured glomerular filtration rate (mGFR). Iohexol is an iodine-like dye used as a diagnostic contrast agent in CT scans.

The researchers found that creatinine-based tests were inaccurate for predicting kidney disease in African populations. This may be because it does not account for unique biological characteristics in this group.

For example, Africans can have lower creatinine levels due to inadequate nutrition (especially low protein ingestion), short stature and low muscle bulk. Creatinine may also be excreted differently in African populations.

Co-lead author of the study, Dr June Fabian of the University of the Witwatersrand, Johannesburg (Wits University), South Africa, said: "The equation that is used to test kidney function is wrong for 1.4 billion people - Africans.

"Kidney disease can be debilitating and ultimately fatal if left untreated. Blood tests are useful to spot early signs of kidney problems - and can help identify people who would benefit from treatment."

ARK researchers used the results of their study, along with population data from Burkina Faso, Ghana, Kenya, Malawi, South Africa and Uganda, to estimate overall levels of kidney disease.

The results suggest that kidney disease prevalence may be substantially higher in Africa than previously thought, increasing from about 1 in 30 people to about 1 in 8 people.

Senior author Dr Laurie Tomlinson of LSHTM, said: "The results of our study show that it is critical to consider whether research into what we consider to be 'normal' blood tests applies to all parts of the world.

"We have shown that for people living in Africa, differences in factors such as childhood health and current nutrition mean that if we're using equations developed in the US and Europe, we may not be  accurately estimating the kidney function of people globally. The burden of kidney disease in Africa has been substantially underestimated and kidney disease has not received the public health focus it requires."

Tests based on cystatin C worked better than creatinine as an indicator of poor kidney function - but the cystatin C testing is not widely used or available in Africa.

The cystatin C test, which would be more suitable in Africa, costs around £16 [US$19], significantly more expensive than the widely-used but less accurate creatinine, at just £3 [US$4].

The findings of the ARK study suggest that switching from the creatinine test of kidney function to cystatin C would be preferable. Ensuring accessibility and enabling doctors to use them should be a priority for Africa, researchers say, and further research for alternative biomarkers is also vital.

Co-lead author Dr Robert Kalyesubula of the MRC/UVRI and LSHTM Uganda Research Unit, said: "Kidney disease has been neglected across the world but more so in countries in Africa, where it has devastating effects.

"Our study provides evidence that kidney disease in Africa is much more rampant than previously thought. This is why it is important that we continue to engage all stakeholders to ensure access to better diagnostic tests, like cystatin C, to improve early detection and care for patients with kidney disease in Africa."

The researchers acknowledge limitations in the study, in particular that inaccuracies in the measurement of creatinine or measured GFR could have impacted the results. The study population was predominantly people with normal levels of serum creatinine, unlike previous studies into measured kidney function which have included many people with known kidney disease.

Finally, while the study is the largest of its kind from Africa and includes measured GFR from three countries, the diversity of African populations means it is possible that there is greater variability in the relationship between creatinine and measured GFR than the team identified, which could affect the accuracy of the estimates of prevalence of kidney disease in the broader population studies.

The South African study was jointly funded by the South African Medical Research Council with funds received from the National Department of Health and the UK Medical Research Council-Newton Fund, and GSK Africa Non-Communicable Diseases Open Lab (via a supporting grant). The study in Uganda and Malawi was funded by a project grant from GSK Africa Non-Communicable Diseases Open Lab.

The ARK Consortium comprises researchers from the University of the Witwatersrand (Wits) in South Africa, including the Medical Research Council/Wits-Agincourt Rural Public Health and Health Transitions Research Unit (Agincourt) in SA's Mpumalanga province; the Malawi Epidemiology and Intervention Research Unit (MEIRU); the MRC/Uganda Virus Research Institute and LSHTM Uganda Research Unit; and LSHTM.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Anti-rejection drug plus immunotherapy could change the lives of kidney transplant patients with cancer